CSIMarket Company Name, Ticker, Customers, else..
 
Vbi Vaccines Inc  (NASDAQ: VBIV)
 

Vbi Vaccines Inc's Suppliers Performance

VBIV's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
VBIV Costs vs Sales of Suppliers Growth

• More on VBIV Suppliers






Vbi Vaccines Inc's Comment on Supply Chain


The company relies on supply agreements with vendors for raw materials required to manufacture its 3-antigen HBV vaccine and eVLP-based pipeline candidates. It is evaluating alternative sources but may encounter challenges in securing timely and cost-effective suppliers. Contractors, including contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), are engaged for clinical trials and manufacturing, with CDMOs dependent on third-party raw material suppliers. The company depends on contractors for vaccine characterization and release. Following the potential sale of its Rehovot facility, manufacturing of the 3-antigen HBV vaccine will be conducted by Brii Israel. Key suppliers include UPMC, which owns the intellectual property for the eVLP vaccine platform licensed to the company, with royalties paid under the ePixis License Agreement until the patent portfolio expired in 2023.

Vbi Vaccines Inc's Comment on Supply Chain


The company relies on supply agreements with vendors for raw materials required to manufacture its 3-antigen HBV vaccine and eVLP-based pipeline candidates. It is evaluating alternative sources but may encounter challenges in securing timely and cost-effective suppliers. Contractors, including contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), are engaged for clinical trials and manufacturing, with CDMOs dependent on third-party raw material suppliers. The company depends on contractors for vaccine characterization and release. Following the potential sale of its Rehovot facility, manufacturing of the 3-antigen HBV vaccine will be conducted by Brii Israel. Key suppliers include UPMC, which owns the intellectual property for the eVLP vaccine platform licensed to the company, with royalties paid under the ePixis License Agreement until the patent portfolio expired in 2023.







VBIV's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Vbi Vaccines Inc 1.48 9.41 -83.99 31
SUBTOTAL 0.00 0.00 0.00 -


Sources: Vbi Vaccines Inc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Vbi Vaccines Inc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.